Winnie Munene is the Patient Safety and Pharmacovigilance Manager, Boehringer Ingelheim. She is majorly responsible for English speaking Sub-Sahara African countries. Winnie holds a Bachelor of Pharmacy from University of Nairobi, an MBA in Healthcare Management from Strathmore Business School and higher diploma in Industrial Pharmaceutical Advanced Training from Purdue University/Kilimanjaro School of Pharmacy. She is an Afrika Kommt fellow 2017 having worked at Merck KGaA in their Germany headquarters for an year.
Winnie is a conscientious healthcare professional passionate about healthcare access and social equity all in the sphere of corporate governance and ethical business practice. She has close to 15 years in both management and leadership roles in Pharmacovilance, Quality and Regulatory Affairs with cross-functional management responsibilities for healthcare access programs and projects. She has a good understanding and vast experience of local and global regulations & guidelines.
Winnie is focused on building her expertise in pharmacovigilance and patient safety management, medical and pharmaceutical compliance, new drug registration for go-to market strategies, regulatory, quality assurance management, which are paramount for access to medicines for developing countries.
Her ultimate career goal is to be a thought leader in healthcare access projects and programs, driving and managing projects that are geared towards medicine and medical technologies access & availability while supporting go-to-market strategies.
She is also a mother to a 10 year old strong-willed lovely girl.

Dr. Anwar is a professional business partner, with strong scientific & medical background, brings up 20 years of experience in the pharmaceutical industry.
Dr. Anwar obtained a bachelor’s degree in veterinary medicine and post graduate Microbiology diploma focusing on Immunology, Bacteriology, Virology and Mycology from Cairo University, Egypt.
Dr. Anwar started the career in 2001 as a medical representative in Egypt and then relocated to UAE in 2007, where she held several seniors roles in different top multinational pharmaceutical companies,” Novartis, GSK, Allergan and Abbvie”.
Dr. Anwar accomplished high level of business acumen with diversified roles in Medical affairs, clinical trials and Pharmacovigilance, within diversified geographical areas

Poste actuel : Point Focal National de la Pharmacovigilance par décision N°723 MSHP-Centre National d’Appui à la lutte contre la Maladie du 09/09/2015, chargé de :
Recueillir et diffuser les informations sur les effets indésirables des médicaments
Analyser et évaluer le lien entre les produits de santé et les effets indésirables par l’imputabilité ;
Coordonner les activités de notifications au sein des structures et programmes de santé ;
Collecter les notifications d’effets indésirables des produits de santé provenant des professionnels de santé des secteurs public et privé des programmes de santé et de l’industrie pharmaceutique ;
Documenter et archiver les informations sur les effets indésirables des produits de santé dans une banque de santé ;
Faire le suivi et la retro information aux notifications des effets indésirables des produits de santé ;
Répondre aux demandes sur les effets indésirables des médicaments
Assurer les échanges avec le centre international de pharmacovigilance de l’OMS : UMC (Uppsala Monitoring center) ;
Programmer et réaliser des enquêtes de pharmacovigilance ;
Générer les signaux et alertes en matière de pharmacovigilance ;
Participation à la 24 ème session ordinaire du conseil d’administration du Centre National d’ Appui à la lutte contre la Maladie (CNAM) ;
Mission de supervision des activités du deuxième passage de la campagne de Chimio prévention du Paludisme Saisonnier chez les enfants de 3 à 59 mois dans le district sanitaire de Sélingue du 01-07 septembre 2016;
Mission de supervision formative de pharmacovigilance dans les districts sanitaires de Djenne et Bandiagara, Région de Mopti du 20 au 29 Novembre 2016.